Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Venous Thrombosis

Free Subscription Articles published in Circulation Retrieve available abstracts of 23 articles: HTML format

Single Articles

February 2026
1. CREAGER MA, Barnes GD, Giri J, Mukherjee D, et al
   2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guideli
   Circulation. 2026 Feb 19. doi: 10.1161/CIR.0000000000001415.
   PubMed     Abstract available
   
   
   
2. TANG W, Li A, Austin TR, Braekkan SK, et al
   Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism.
   Circulation. 2026 Feb 16. doi: 10.1161/CIRCULATIONAHA.125.074493.
   PubMed     Abstract available
   
   
   November 2025
3. LOOKSTEIN RA, Konstantinides SV, Weinberg I, Dohad SY, et al
   Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes from the STORM-PE Trial.
   Circulation. 2025 Nov 3. doi: 10.1161/CIRCULATIONAHA.125.077232.
   PubMed     Abstract available
   
   
   September 2025
4. WHITE RJ, Roto D, Lachant D
   Letter by White et al Regarding Article, "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial".
   Circulation. 2025;152:e269-e270.
   PubMed    
   
   
   
5. JABER WA, Gonsalves CF, Stortecky S, Giri J, et al
   Response by Jaber et al to Letter Regarding Article, "Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial".
   Circulation. 2025;152:e271-e272.
   PubMed    
   
   
   
6. JI L, Zhang H
   Letter by Ji and Zhang Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e90-e91.
   PubMed    
   
   
   
7. HE Z, Wang C, Tian H
   Letter by He et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e88.
   PubMed    
   
   
   
8. LIU G, Fu C, Xie J
   Letter by Liu et al Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e92-e93.
   PubMed    
   
   
   
9. SANTINI P, Pola R
   Letter by Santini and Pola Regarding Article, "Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
   Circulation. 2025;152:e89.
   PubMed    
   
   
   
10. YAMASHITA Y, Morimoto T, Kimura T
    Response by Yamashita et al to Letter Regarding Article, "Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)".
    Circulation. 2025;152:e94-e95.
    PubMed    
    
    
    March 2025
11. TAKAHASHI EA, Sista AK, Addison D, Bikdeli B, et al
    Disparities in Current Pulmonary Embolism Management and Outcomes: A Scientific Statement From the American Heart Association.
    Circulation. 2025 Mar 20. doi: 10.1161/CIR.0000000000001306.
    PubMed     Abstract available
    
    
    February 2025
12. RAO SV, Gutierrez JAT
    A Win for Clinical Evidence: The First Head-to-Head Trial of Interventional Strategies for the Treatment of Pulmonary Embolism.
    Circulation. 2025;151:274-276.
    PubMed    
    
    
    November 2024
13. YAMASHITA Y, Morimoto T, Muraoka N, Shioyama W, et al
    Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial).
    Circulation. 2024 Nov 18. doi: 10.1161/CIRCULATIONAHA.124.072758.
    PubMed     Abstract available
    
    
    October 2024
14. JABER WA, Gonsalves CF, Stortecky S, Horr S, et al
    Large-bore Mechanical Thrombectomy Versus Catheter-directed Thrombolysis in the Management of Intermediate-risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.
    Circulation. 2024 Oct 29. doi: 10.1161/CIRCULATIONAHA.124.072364.
    PubMed     Abstract available
    
    
    
15. DELCROIX M, Pepke-Zaba J, D'Armini AM, Fadel E, et al
    Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy.
    Circulation. 2024;150:1354-1365.
    PubMed     Abstract available
    
    
    September 2024
16. ROSENFIELD K, Bowers TR, Barnett CF, Davis GA, et al
    Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report from the Pulmonary Embolism Research Collaborative.
    Circulation. 2024 Sep 12. doi: 10.1161/CIRCULATIONAHA.124.067482.
    PubMed     Abstract available
    
    
    
17. SINGH S, Kumar P, Padwad YS, Jaffer FA, et al
    Targeting Fibrinolytic Inhibition for Venous Thromboembolism Treatment: Overview of an Emerging Therapeutic Approach.
    Circulation. 2024;150:884-898.
    PubMed     Abstract available
    
    
    June 2024
18. 
    Correction to: Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024;149:e1412.
    PubMed    
    
    
    March 2024
19. AGGARWAL V, Giri J, Visovatti SH, Mahmud E, et al
    Status and Future Directions for Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease With and Without Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circulation. 2024 Mar 7. doi: 10.1161/CIR.0000000000001197.
    PubMed     Abstract available
    
    
    December 2023
20. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    PubMed     Abstract available
    
    
    November 2023
21. GOTO S, Goto S
    Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis.
    Circulation. 2023;148:1677-1679.
    PubMed    
    
    
    
22. HOSOKAWA K, Watanabe H, Taniguchi Y, Ikeda N, et al
    A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial.
    Circulation. 2023 Nov 13. doi: 10.1161/CIRCULATIONAHA.123.067528.
    PubMed    
    
    
    March 2023
23. LASSEN MCH, Modin D, Skaarup KG, Johansen ND, et al
    Risk of Incident Thromboembolic and Ischemic Events After COVID-19 Vaccination Compared With SARS-CoV-2 Infection.
    Circulation. 2023;147:843-845.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Venous Thrombosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum